$ENTA
ENANTA PHARMACEUTICALS INC

2017 Q3 Form 10-K Financial Statement

#000156459017024794 Filed on December 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2017 Q1
Revenue $75.93M $7.511M $8.959M
YoY Change 491.29% -46.27% -31.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.120M $5.230M $5.460M
YoY Change 15.32% 22.2% 23.25%
% of Gross Profit
Research & Development $16.51M $15.41M $13.00M
YoY Change 43.57% 42.88% 42.23%
% of Gross Profit
Depreciation & Amortization $570.0K $550.0K $530.0K
YoY Change 26.67% 25.0% 23.26%
% of Gross Profit
Operating Expenses $21.63M $20.64M $13.00M
YoY Change 35.7% 91.38% 42.23%
Operating Profit -$9.506M
YoY Change 1582.48%
Interest Expense $660.0K $600.0K $8.000K
YoY Change 40.43% 5354.55% -27.27%
% of Operating Profit
Other Income/Expense, Net $660.0K $600.0K $549.0K
YoY Change 40.13% 34.23% 16.31%
Pretax Income $54.96M -$12.53M -$8.957M
YoY Change -2189.73% 1851.71% 9531.18%
Income Tax -$18.45M $4.103M $3.565M
% Of Pretax Income -33.56%
Net Earnings $36.51M -$8.426M -$5.392M
YoY Change -2125.97% 683.09% 227.78%
Net Earnings / Revenue 48.08% -112.18% -60.19%
Basic Earnings Per Share $1.91 -$0.44 -$0.28
Diluted Earnings Per Share $1.86 -$0.44 -$0.28
COMMON SHARES
Basic Shares Outstanding 19.08M 19.05M
Diluted Shares Outstanding 19.05M

Balance Sheet

Concept 2017 Q3 2017 Q2 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $223.7M $192.0M $175.6M
YoY Change 6.46% -12.13% -20.33%
Cash & Equivalents $65.68M $22.26M $19.21M
Short-Term Investments $158.0M $169.8M $156.4M
Other Short-Term Assets $3.500M $6.600M $6.100M
YoY Change -61.96% -29.03% -34.41%
Inventory
Prepaid Expenses
Receivables $10.61M $7.500M $8.959M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $237.8M $206.1M $190.6M
YoY Change 2.44% -14.76% -21.46%
LONG-TERM ASSETS
Property, Plant & Equipment $8.049M $8.100M $8.526M
YoY Change 0.56% 8.01% 10.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $70.00M $43.30M $65.30M
YoY Change 118.07% 65.27% 159.13%
Other Assets $10.70M $18.30M $14.50M
YoY Change 18.89% 181.54% 141.67%
Total Long-Term Assets $88.82M $69.70M $88.37M
YoY Change 80.81% 73.62% 126.99%
TOTAL ASSETS
Total Short-Term Assets $237.8M $206.1M $190.6M
Total Long-Term Assets $88.82M $69.70M $88.37M
Total Assets $326.6M $275.8M $279.0M
YoY Change 16.13% -2.18% -0.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.714M $5.500M $4.056M
YoY Change 9.98% 169.08% 57.7%
Accrued Expenses $7.970M $5.600M $5.098M
YoY Change 76.64% 22.19% 93.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $20.98M $11.10M $9.154M
YoY Change 165.97% 16.0% -23.64%
LONG-TERM LIABILITIES
Long-Term Debt $1.100M $600.0K $600.0K
YoY Change 83.33% 0.0% -14.29%
Other Long-Term Liabilities $2.410M $3.300M $2.355M
YoY Change 18.02% 68.11% 29.9%
Total Long-Term Liabilities $2.410M $3.900M $2.355M
YoY Change 18.02% 98.68% 29.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.98M $11.10M $9.154M
Total Long-Term Liabilities $2.410M $3.900M $2.355M
Total Liabilities $24.96M $15.00M $12.95M
YoY Change 120.1% 16.04% -14.71%
SHAREHOLDERS EQUITY
Retained Earnings $45.36M $17.27M
YoY Change 64.06% -43.41%
Common Stock $256.4M $248.8M
YoY Change 5.85% 5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $301.7M $260.9M $266.0M
YoY Change
Total Liabilities & Shareholders Equity $326.6M $275.8M $279.0M
YoY Change 16.13% -2.18% -0.94%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2017 Q1
OPERATING ACTIVITIES
Net Income $36.51M -$8.426M -$5.392M
YoY Change -2125.97% 683.09% 227.78%
Depreciation, Depletion And Amortization $570.0K $550.0K $530.0K
YoY Change 26.67% 25.0% 23.26%
Cash From Operating Activities $57.30M -$4.790M -$3.010M
YoY Change -2790.14% 127.01% -129.92%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K -$740.0K -$580.0K
YoY Change -42.86% 21.31% -61.59%
Acquisitions
YoY Change
Other Investing Activities -$14.67M $8.400M $2.380M
YoY Change 155.57% -127.26% 124.53%
Cash From Investing Activities -$14.90M $7.660M $1.800M
YoY Change 142.67% -124.37% -491.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.010M 190.0K -210.0K
YoY Change 1342.86% -90.31% -139.62%
NET CHANGE
Cash From Operating Activities 57.30M -4.790M -3.010M
Cash From Investing Activities -14.90M 7.660M 1.800M
Cash From Financing Activities 1.010M 190.0K -210.0K
Net Change In Cash 43.41M 3.060M -1.420M
YoY Change -629.39% -109.69% -114.02%
FREE CASH FLOW
Cash From Operating Activities $57.30M -$4.790M -$3.010M
Capital Expenditures -$240.0K -$740.0K -$580.0K
Free Cash Flow $57.54M -$4.050M -$2.430M
YoY Change -3464.91% 170.0% -121.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Entity Registrant Name
EntityRegistrantName
ENANTA PHARMACEUTICALS INC
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001177648
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Trading Symbol
TradingSymbol
ENTA
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.14
CY2017 us-gaap Net Income Loss
NetIncomeLoss
17710000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.09
CY2017 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
65000000
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8004000
CY2017Q3 us-gaap Assets
Assets
326637000
CY2016Q3 us-gaap Assets
Assets
281277000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3714000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3377000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7970000
CY2017Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
9298000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20982000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7889000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8049000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4512000
CY2017 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
202000
CY2017Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
762000
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2410000
CY2017Q3 us-gaap Liabilities
Liabilities
24961000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
191000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256241000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-112000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
45356000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
301676000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
326637000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19120000
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3536000
CY2017Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
157994000
CY2016Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
193507000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10614000
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12841000
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19126006
CY2017Q1 dei Entity Public Float
EntityPublicFloat
491133874
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65675000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16577000
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9231000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
237819000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
232156000
CY2017Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
70038000
CY2016Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
32119000
CY2017Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
10123000
CY2016Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
8390000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2016Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2017Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
807000
CY2016Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1251000
CY2016Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
159000
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2042000
CY2016Q3 us-gaap Liabilities
Liabilities
11341000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
190000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
242081000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
27646000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
269936000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281277000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19036000
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19120000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19036000
CY2016 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
30000000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
26947000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32560000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9237000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20749000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
78200000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
57427000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
30841000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
124148000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-131000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
133000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
79125000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13071000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19224000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21652000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5838000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19066000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
133000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19295000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
133000
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.13
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19407000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
280651000
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18673000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2333000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2506000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10894000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46463000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
21666000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
78992000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.23
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18929000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-131000
CY2015 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
125000000
CY2017 us-gaap Royalty Revenue
RoyaltyRevenue
37814000
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
57692000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
34077000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1079000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13543000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
36732000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
968000
CY2017 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
213000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-131000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
13071000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
9354000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2137000
CY2017 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1654000
CY2015 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
11028000
CY2017 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
1229000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
148654000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
726000
CY2015 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
1814000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
236157000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1026000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9354000
CY2016 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
1747000
CY2016 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
518000
CY2015 enta Premium On Marketable Securities
PremiumOnMarketableSecurities
3042000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-702000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1511000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2244000
CY2017 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
213000
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1747000
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1814000
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
576000
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
1803000
CY2017 us-gaap Revenues
Revenues
102814000
CY2016 us-gaap Revenues
Revenues
88268000
CY2015 us-gaap Revenues
Revenues
160880000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57451000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40461000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23189000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16966000
CY2015 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-2337000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6680000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-543000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-227000
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1199000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
649000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
52653000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
35809000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
76673000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
196304000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
239287000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
153504000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
108407000
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
10018000
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2210000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4738000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17579000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-78000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-9000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
20000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-34000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
35000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
5838000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1661000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
639000
CY2016 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-2294000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2227000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2448000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13565000
CY2016 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-433000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5678000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
964000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
633000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1451000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3443000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1858000
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
9511000
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
548000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
478000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
397000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
251371000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
192429000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
1588000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
318000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2336000
CY2015 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
163000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4572000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-43663000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-88186000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1079000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1026000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
726000
CY2017 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
213000
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1747000
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1814000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
202000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
73000
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
68000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1017000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2705000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2540000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
49098000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5149000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8973000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21726000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30699000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
12616000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
40072000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
637000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1562000
CY2015 enta Fixed Assets Financed By Landlord
FixedAssetsFinancedByLandlord
239000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
598000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enanta Pharmaceuticals, Inc. (the &#8220;Company&#8221;), incorporated in Delaware in 1995, is <font style="Background-color:#FFFFFF;">a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily for the treatment of viral infections and liver diseases. The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through the Company&#8217;s collaboration with&#160;AbbVie and marketed as part of AbbVie&#8217;s new direct-acting antiviral (DAA) regimen under the tradenames MAVYRET&#8482; (U.S.) or MAVIRET&#8482; (ex-U.S.) (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C virus, or HCV. The other protease inhibitor under the Company&#8217;s HCV collaboration is part of AbbVie&#8217;s initial DAA regimens for the treatment of chronic HCV marketed under the tradenames VIEKIRA PAK<sup style="font-size:85%; vertical-align:top">&#174; </sup>(paritaprevir/ritonavir/ombitasvir/dasabuvir) (U.S.) or VIEKIRAX<sup style="font-size:85%; vertical-align:top">&#174;</sup> (paritaprevir/ritonavir/ombitasvir) (ex-U.S.). </font><font style="color:#000000;">The royalties from the AbbVie collaboration and the Company&#8217;s existing financial resources provides funding to support the Company&#8217;s wholly owned research and development efforts</font><font style="Background-color:#FFFFFF;">, which are currently focused on the following disease targets: </font>hepatitis B virus (&#8220;HBV&#8221;); non-alcoholic steatohepatitis (&#8220;NASH&#8221;); primary biliary cholangitis (&#8220;PBC&#8221;); and respiratory syncytial virus (&#8220;RSV&#8221;).</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approvals, prior to commercialization. These efforts require significant amounts of capital and adequate personnel infrastructure and compliance reporting capabilities.</p></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to,&#160;<font style="Background-color:#FFFFFF;">management&#8217;s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; valuation of warrants, Series&#160;1 nonconvertible preferred stock and stock-based awards; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets.&#160;</font>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Customers and Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, accounts receivable and unbilled receivables. The Company has all cash and investment balances at one accredited financial institution, including cash in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has historically generated all of its revenue from its collaborative research and license agreements as well as a U.S. government contract (see Note 7). As of September 30, 2017 and 2016, accounts receivable consisted of amounts due from the Company&#8217;s principal collaborator (see Note 7). </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is completely dependent on third-party manufacturers for product supply for preclinical and clinical research activities in its non-partnered programs. The Company relies and expects to continue to rely exclusively on several manufacturers to supply it with its requirements for the active pharmaceutical ingredients related to these programs. These research programs would be adversely affected by a significant interruption in the supply of its active pharmaceutical ingredients. </p></div>
CY2017 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2016 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2015 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0
CY2017Q3 enta Number Of Revenue Generating Contract
NumberOfRevenueGeneratingContract
1
CY2017Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1569000
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
240921000
CY2016Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1410000
CY2017 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2016 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2015 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
228211000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
188000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
228032000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
225596000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
80000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
50000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
225626000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15103000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13102000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7054000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5098000
CY2017Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
3156000
CY2016Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
899000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2829000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2384000
CY2017Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1130000
CY2016Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
459000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
456000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
393000
CY2014Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1775000
CY2015 enta Warrants Granted
WarrantsGranted
0
CY2015 enta Warrants Expired
WarrantsExpired
0
CY2015Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1775000
CY2016 enta Warrants Granted
WarrantsGranted
0
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2298000
CY2017Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
79000
CY2016Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
73000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
320000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
304000
CY2017Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1175000
CY2016Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
745000
CY2017Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
676000
CY2016Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
696000
CY2017Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
379000
CY2016Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
458000
CY2017Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
180000
CY2016Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
143000
CY2017 enta Collaboration Agreement Date Abb Vie
CollaborationAgreementDateAbbVie
2006-11-27
CY2017 enta Collaboration Agreement Date Nih
CollaborationAgreementDateNIH
2011-09-30
CY2015 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
209000
CY2016 enta Warrants Expired
WarrantsExpired
0
CY2016Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1775000
CY2017 enta Warrants Granted
WarrantsGranted
0
CY2017 enta Warrants Expired
WarrantsExpired
0
CY2017 enta Warrants Exercised
WarrantsExercised
745000
CY2017Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1030000
CY2014Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2015Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2016Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2017 enta Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
0.01
CY2017Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0177
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0185
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M11D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.60
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1895000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
613000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
138000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2283000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1350000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.75
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.93
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.95
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
18.73
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.36
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
30.35
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1503000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1326000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
813000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
956000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2172000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2025000
CY2017Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
28.52
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7369000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37821000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
37596000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
24705000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1503000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7705000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4827000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.52
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.12
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.77
CY2017Q3 enta Target To Achieve Percentage
TargetToAchievePercentage
1.00
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13071000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9354000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5838000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
24613000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M13D
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
341000
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
295000
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
622000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2161000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1475000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
605000
CY2017 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2025000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2062000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2117000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2172000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2229000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2093000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10673000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
79000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
86000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
93000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
101000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
99000
CY2017Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
458000
CY2016Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2017 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
598000
CY2017 enta Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
5000000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
10078000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
12233000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
35040000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2136000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
7371000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-151000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-159000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1880000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.026
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.074
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.038
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.045
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.026
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.005
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.030
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.013
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.343
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.335
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.370
CY2017Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7899000
CY2016Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4919000
CY2017Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1199000
CY2016Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2052000
CY2017Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2172000
CY2016Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1498000
CY2017Q3 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
67000
CY2017Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11337000
CY2016Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8469000
CY2017Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2016Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2017Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11337000
CY2016Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8469000
CY2017Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1026000
CY2016Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
68000
CY2017Q3 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
188000
CY2016Q3 us-gaap Deferred Tax Liabilities Other Comprehensive Income
DeferredTaxLiabilitiesOtherComprehensiveIncome
11000
CY2017Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1214000
CY2016Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
79000
CY2017Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10123000
CY2016Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
8390000
CY2016Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
745000
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
448000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
134000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
294000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
355000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
16000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
59000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
13000
CY2017Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1175000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
712000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
513000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
382000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
471000
CY2016Q4 us-gaap Revenues
Revenues
10417000
CY2017Q1 us-gaap Revenues
Revenues
8959000
CY2017Q2 us-gaap Revenues
Revenues
7511000
CY2017Q3 us-gaap Revenues
Revenues
75927000
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9734000
CY2016Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
17463000
CY2017Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
18465000
CY2017Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
20640000
CY2017Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21632000
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
524000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
549000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
600000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
660000
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1542000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3565000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4103000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-18447000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-4980000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5392000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-8426000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
36508000
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.86
CY2015Q4 us-gaap Revenues
Revenues
48445000
CY2016Q1 us-gaap Revenues
Revenues
13004000
CY2016Q2 us-gaap Revenues
Revenues
13978000
CY2016Q3 us-gaap Revenues
Revenues
12841000
CY2015Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12851000
CY2016Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
13569000
CY2016Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15067000
CY2016Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15940000
CY2015Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
329000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
472000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
447000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1552000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-434000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
826000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
26189000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1645000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-1076000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1802000
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.39
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09

Files In Submission

Name View Source Status
0001564590-17-024794-index-headers.html Edgar Link pending
0001564590-17-024794-index.html Edgar Link pending
0001564590-17-024794.txt Edgar Link pending
0001564590-17-024794-xbrl.zip Edgar Link pending
enta-10k_20170930.htm Edgar Link pending
enta-20170930.xml Edgar Link completed
enta-20170930.xsd Edgar Link pending
enta-20170930_cal.xml Edgar Link unprocessable
enta-20170930_def.xml Edgar Link unprocessable
enta-20170930_lab.xml Edgar Link unprocessable
enta-20170930_pre.xml Edgar Link unprocessable
enta-ex1018_1136.htm Edgar Link pending
enta-ex1019_1137.htm Edgar Link pending
enta-ex211_12.htm Edgar Link pending
enta-ex231_11.htm Edgar Link pending
enta-ex311_10.htm Edgar Link pending
enta-ex312_8.htm Edgar Link pending
enta-ex321_9.htm Edgar Link pending
enta-ex43_1302.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g20171211194947181799.jpg Edgar Link pending
g20171211194947221800.jpg Edgar Link pending
g201712111949546421097.jpg Edgar Link pending
g201712111950000761281.jpg Edgar Link pending
g201712111950000931282.jpg Edgar Link pending
g201712111950111421283.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending